Alexza Pharmaceuticals, Inc. (ALXA)
Q2 2012 Earnings Call
August 8, 2012 5:00 pm ET
Mark K. Oki – Senior Vice President-Finance, Chief Financial Officer and Secretary
Thomas B. King – President and Chief Executive Officer
Roy Buchanan – JMP Securities
Steve Brozak – WBB Securities, LLC
Good afternoon, everyone, and welcome to the Alexza Pharmaceuticals 2012 Second Quarter Financial Results and General Business Update Conference Call. At this time, all participants are in a listen-only mode for the conference call. Following the prepared remarks, there will be a question-and-answer session. (Operator Instructions) Today’s conference is also being recorded. And if you have any objections, you may disconnect at this time.
I would now like to turn today’s conference over to Mr. Mark Oki of Alexza. Mr. Oki, you may begin.
Mark K. Oki
Thank you. Good afternoon and welcome to our 2012 second quarter financial results and general business update conference call. Before we get started, I would like to remind you that the matters discussed on this call contain forward-looking statements that involve risks and uncertainties, including those related to the Company’s ability to address the issues raised in the May 2012 CRL, the eventual prospects that ADASUVE will be approved for marketing in the U.S. or other locations, and timing of the EMA review of the ADASUVE MAA, our ability to commercialize products, the timing of the commercialization of our products, our projected revenue and expenses, and the ability of Alexza to support operations based on existing cash resources.
Actual results may differ materially from the results predicted, and recorded results should not be considered an indication of future performance. These and other risk factors are more fully discussed in our quarterly report on Form 10-Q that we filed with the SEC earlier today most particularly under the caption Risk Factors. Alexza disclaims any obligation to update or revise any forward-looking statement made on this call as a result of new information or future developments.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts